There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAB Biotherapeutics (SABS – Research Report) and Geron (GERN – Research Report) with bullish sentiments.
SAB Biotherapeutics (SABS)
Chardan Capital analyst Keay Nakae reiterated a Buy rating on SAB Biotherapeutics today and set a price target of $3.00. The company’s shares closed last Wednesday at $0.88.
According to TipRanks.com, Nakae is a 2-star analyst with an average return of
SAB Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See Insiders’ Hot Stocks on TipRanks >>
Geron (GERN)
In a report released today, Gil Blum from Needham reiterated a Buy rating on Geron, with a price target of $4.00. The company’s shares closed last Wednesday at $3.09.
According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of
Geron has an analyst consensus of Strong Buy, with a price target consensus of $5.00, a 52.4% upside from current levels. In a report issued on June 4, Robert W. Baird also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SABS:
- SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
- SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
- SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
- SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
- SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
